InnoCare Pharma Limited provided earnings guidance for the year ended 31 December 2023. Based on a preliminary estimate by the finance department, the net loss attributable to owners of the parent company in 2023 is expected to be approximately RMB 656 million, representing a decrease in loss of approximately 26% as compared with the corresponding period of the previous year. The net loss after excluding non-recurring gains or losses attributable to owners of the parent company was approximately RMB 654 million, representing a decrease of approximately 32% as compared with the corresponding period of the previous year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.13 HKD | -0.58% | +0.20% | -25.54% |
09:15am | Innocare Pharma Posts Q1 Loss | MT |
05-13 | InnoCare Logs Loss in Q1 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.54% | 1.31B | |
+4.24% | 111B | |
+11.35% | 105B | |
-12.44% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-9.88% | 16.96B | |
+2.54% | 13.7B | |
+36.95% | 12.45B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023